CN1938042B - 芳香族阳离子肽在制备用于减轻氧化性损伤药物中的应用 - Google Patents

芳香族阳离子肽在制备用于减轻氧化性损伤药物中的应用 Download PDF

Info

Publication number
CN1938042B
CN1938042B CN2005800082000A CN200580008200A CN1938042B CN 1938042 B CN1938042 B CN 1938042B CN 2005800082000 A CN2005800082000 A CN 2005800082000A CN 200580008200 A CN200580008200 A CN 200580008200A CN 1938042 B CN1938042 B CN 1938042B
Authority
CN
China
Prior art keywords
dextrorotation
dmt
use according
peptide
arginine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CN2005800082000A
Other languages
English (en)
Chinese (zh)
Other versions
CN1938042A (zh
Inventor
黑兹尔·H·塞托
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cornell Research Foundation Inc
Original Assignee
Cornell Research Foundation Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cornell Research Foundation Inc filed Critical Cornell Research Foundation Inc
Publication of CN1938042A publication Critical patent/CN1938042A/zh
Application granted granted Critical
Publication of CN1938042B publication Critical patent/CN1938042B/zh
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1019—Tetrapeptides with the first amino acid being basic

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
CN2005800082000A 2004-01-23 2005-01-21 芳香族阳离子肽在制备用于减轻氧化性损伤药物中的应用 Expired - Lifetime CN1938042B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US53884104P 2004-01-23 2004-01-23
US60/538,841 2004-01-23
PCT/US2005/002119 WO2005072295A2 (en) 2004-01-23 2005-01-21 Methods for reducing oxidative damage

Publications (2)

Publication Number Publication Date
CN1938042A CN1938042A (zh) 2007-03-28
CN1938042B true CN1938042B (zh) 2010-06-02

Family

ID=34826019

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2005800082000A Expired - Lifetime CN1938042B (zh) 2004-01-23 2005-01-21 芳香族阳离子肽在制备用于减轻氧化性损伤药物中的应用

Country Status (13)

Country Link
US (8) US7550439B2 (https=)
EP (1) EP1722807A4 (https=)
JP (1) JP4931604B2 (https=)
KR (1) KR101159254B1 (https=)
CN (1) CN1938042B (https=)
AU (1) AU2005208821B8 (https=)
BR (1) BRPI0507053A (https=)
CA (7) CA2851972C (https=)
IL (5) IL177030A (https=)
NZ (1) NZ549393A (https=)
RU (1) RU2376028C2 (https=)
WO (1) WO2005072295A2 (https=)
ZA (1) ZA200607013B (https=)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2656854T1 (sl) 2003-02-04 2015-09-30 Cornell Research Foundation, Inc. Uporabe aromatsko-kationskega peptida
JP4879020B2 (ja) * 2003-05-01 2012-02-15 コーネル リサーチ ファウンデイション インコーポレイテッド 細胞に分子を送達する方法及び担体複合体
CA2851972C (en) * 2004-01-23 2015-06-23 Cornell Research Foundation, Inc. Methods for reducing oxidative damage
US8822542B2 (en) 2004-10-20 2014-09-02 Vanderbilt University Isoketal scavengers and mitigation of disorders involving oxidative injury
GB0517090D0 (en) * 2005-08-19 2005-09-28 Tcp Innovations Ltd ApoE mimetic agents
AU2019257440B2 (en) * 2005-09-16 2021-12-16 Cornell Research Foundation, Inc. Methods for reducing CD36 expression
CA2947335A1 (en) * 2005-09-16 2007-03-29 Cornell Research Foundation, Inc. Methods for reducing cd36 expression
AU2014203126B2 (en) * 2005-09-16 2016-03-10 Cornell Research Foundation, Inc. Methods for reducing cd36 expression
AU2007277193B2 (en) 2006-07-25 2013-06-13 Hough Ear Institute Methods for treating acute acoustic trauma
EP2114427B1 (en) 2007-01-30 2014-06-25 New York University Peptides for treatment of conditions associated with nitric oxide
JP4461159B2 (ja) * 2007-06-14 2010-05-12 ヤマハファインテック株式会社 プリント基板の検査装置および検査方法
EP3103467A1 (en) * 2008-02-07 2016-12-14 Cornell University Methods for preventing or treating insulin resistance
DK2262520T3 (en) * 2008-02-26 2017-08-07 Univ Cornell COMPOSITIONS FOR PREVENTION AND TREATMENT OF Kidney Injury
DE102008061044A1 (de) * 2008-12-11 2010-06-17 Henkel Ag & Co. Kgaa Zusammensetzung mit antioxidativ wirksamen Peptiden
EP3563862B1 (en) 2009-03-20 2021-05-05 The General Hospital Corporation d/b/a Massachusetts General Hospital D-arg-2'6'-dimethyltyrosine-lys-phe-nh2 for use in the prevention of secondary complications of burn injuries
EP2477594A4 (en) * 2009-07-15 2013-03-13 Univ Vanderbilt ISOKETAL CATCHER AND TREATMENT OF DISEASES WITH OXIDATIVE INJURY
CN105031605A (zh) * 2009-08-12 2015-11-11 康奈尔大学 预防或治疗代谢综合症的方法
PL2470191T3 (pl) * 2009-08-24 2014-09-30 Stealth Peptides Int Inc Sposoby i kompozycje do profilaktyki lub leczenia stanów okulistycznych
EP2485749A4 (en) * 2009-10-05 2013-07-24 Univ Cornell METHOD FOR THE PREVENTION AND TREATMENT OF HEART FAILURE
EP3266462A1 (en) * 2009-12-31 2018-01-10 Stealth Peptides International, Inc. Methods for performing a coronary artery bypass graft procedure
CN103751763A (zh) * 2009-12-31 2014-04-30 康肽德生物医药技术有限公司 用于预防或治疗血管阻塞损伤的方法
AU2011207432A1 (en) * 2010-01-25 2012-08-02 Cornell University Aromatic-cationic peptides and uses of same
EP3332795A1 (en) * 2010-02-26 2018-06-13 Cornell University Cornell Center For Technology, Enterprise & Commercialization ("CCTEC") Mitochondrial-targeted antioxidants protect against mechanical ventilation-induced diaphragm dysfunction and skeletal muscle atrophy
EP3375449A1 (en) 2010-03-15 2018-09-19 Stealth Peptides International, Inc. Combination therapies using cyclosporine and aromatic cationic peptides
US20110245182A1 (en) * 2010-04-06 2011-10-06 Perricone Nicholas V Topical Uses of Szeto-Schiller Peptides
US20110245183A1 (en) * 2010-04-06 2011-10-06 Perricone Nicholas V Topical Uses of Szeto-Schiller Peptides
JP2013532124A (ja) * 2010-05-03 2013-08-15 ステルス ペプチドズ インターナショナル インコーポレイテッド 芳香族系陽イオンペプチド及びその使用
HUP1000243A2 (en) 2010-05-06 2012-01-30 Avidin Kft 8-hidroxy-quinoline derivatives
JP6319738B2 (ja) * 2010-07-09 2018-05-09 ステルス ペプチドズ インターナショナル インコーポレイテッド 虚血／再灌流障害に続くノーリフローの予防又は処置方法
WO2012009171A2 (en) * 2010-07-15 2012-01-19 The Schepens Eye Research Institute, Inc. Compositions and methods of treatment of corneal endothelium disorders
CA2810668A1 (en) 2010-09-08 2012-03-15 Halozyme, Inc. Methods for assessing and identifying or evolving conditionally active therapeutic proteins
US20120083452A1 (en) * 2010-09-30 2012-04-05 Perricone Nicholas V Topical Anesthetic Uses of Szeto-Schiller Peptides
ES2893825T3 (es) 2011-02-04 2022-02-10 Hough Ear Inst Métodos de tratamiento de lesiones cerebrales
AU2012271691A1 (en) * 2011-06-14 2014-01-16 Stealth Peptides International, Inc. Aromatic-cationic peptides and uses of same
CN102327600A (zh) * 2011-09-14 2012-01-25 中国人民解放军军事医学科学院放射与辐射医学研究所 用于预防和治疗辐射损伤的rx31肽
AU2012315586B2 (en) * 2011-09-29 2017-07-20 Mayo Foundation For Medical Education And Research Aromatic-cationic peptides and methods for using same
WO2013059071A1 (en) * 2011-10-17 2013-04-25 Cornell University Aromatic-cationic peptides and uses of same
HK1204988A1 (en) * 2012-02-22 2015-12-11 Stealth Peptides International, Inc. Methods and compositions for preventing or treating ophthalmic conditions
CA2865409C (en) * 2012-02-23 2020-07-21 Cornell University Aromatic-cationic peptides and uses of same
KR101721678B1 (ko) 2012-03-08 2017-03-31 할로자임, 아이엔씨 조건부 활성 항-표피 성장 인자 수용체 항체 및 이의 사용 방법
JP6317324B2 (ja) * 2012-03-30 2018-04-25 ステルス ペプチドズ インターナショナル インコーポレイテッド 神経障害を予防および処置するための方法および組成物
CN110339339A (zh) 2013-03-01 2019-10-18 康德生物医疗技术公司 治疗线粒体疾病的方法
EP3626252A1 (en) 2013-03-01 2020-03-25 Stealth Biotherapeutics Corp Methods and compositions for the prevention or treatment of barth syndrome
WO2014210062A1 (en) 2013-06-26 2014-12-31 Stealth Peptides International, Inc. Methods for the regulation of matrix metalloproteinase expression
US10047395B2 (en) 2013-06-26 2018-08-14 Stealth Biotherapeutics Corp Methods and compositions for detecting and diagnosing diseases and conditions
WO2015017861A1 (en) 2013-08-02 2015-02-05 Stealth Peptides International, Inc. Methods and compositions for the prevention and treatment of friedreich's ataxia
JP6480921B2 (ja) * 2013-09-27 2019-03-13 コーネル ユニヴァーシティー コレステロール誘発性ミトコンドリア機能不全を治療するための芳香族カチオン性ペプチドの使用
EP3052115A4 (en) * 2013-09-30 2017-09-27 Cornell University Cardiolipin-targeted peptides inhibit beta-amyloid oligomer toxicity
EP3060573B1 (en) 2013-10-23 2019-07-17 Kaneka Corporation Tetrapeptide compound and method for producing same
CA2932408A1 (en) * 2013-12-02 2015-06-11 Stealth Biotherapeutics Corp Compositions and methods for treating vitiligo
WO2015095077A1 (en) * 2013-12-16 2015-06-25 Cornell University Methods and compositions for treating and preventing cognitive dysfunction
EP3071591B1 (en) * 2014-01-22 2021-05-05 Agency For Science, Technology And Research Antimicrobial peptidomimetics
US9314457B2 (en) 2014-06-19 2016-04-19 The University Of Utah Research Foundation Methods of treating and preventing vascular instability diseases
EP3160984B1 (en) 2014-06-25 2021-04-14 Flamma S.P.A. Process for preparing d-arginyl-2,6-dimethyl-l-tyrosyl-l-lysyl-l-phenylalaninamide
WO2016001042A1 (en) 2014-06-30 2016-01-07 Flamma S.P.A. Process for the production of d-arginyl-2,6-dimethyl-l-tyrosyl-l-lysyl-l-phenylalaninamide
WO2016004093A2 (en) * 2014-07-01 2016-01-07 Stealth Biotherapeutics Corp Therapeutic compositions including galectin-3 inhibitors and uses thereof
WO2016200364A1 (en) * 2015-06-08 2016-12-15 Stealth Peptides International, Inc. THERAPEUTIC COMPOSITIONS INCLUDING SkQ COMPOUNDS AND USES THEREOF
US11266716B2 (en) * 2015-10-22 2022-03-08 The Feinstein Institutes For Medical Research Use of dermcidin in sterile inflammatory conditions
CA3006698A1 (en) * 2015-11-30 2017-06-08 Peter Schiller Aromatic-cationic peptides conjugated to antioxidants and their use in treating complex regional pain syndrome
RU2613910C1 (ru) * 2015-12-08 2017-03-21 Федеральное государственное бюджетное учреждение науки Государственный научный центр Российской Федерации - Институт медико-биологических проблем Российской академии наук (ГНЦ РФ - ИМБП РАН) Способ определения тканевой гипоксии скелетных мышц и миокарда при гиподинамии
US20170224764A1 (en) * 2016-02-10 2017-08-10 Cornell University Therapeutic targeting of mitochondria to prevent osteoarthritis
CN107041946A (zh) * 2017-03-24 2017-08-15 南京大学 化合物ss‑31在制备治疗动脉粥样硬化及相关疾病药物或制剂上的应用
EP3811451A4 (en) * 2018-05-23 2022-04-06 University of Pittsburgh - of the Commonwealth System of Higher Education HEART SPECIFIC TARGETING PEPTIDE (CTP), COMPOSITIONS AND USES THEREOF
EP4178589A4 (en) * 2020-07-09 2024-07-24 Musc Foundation for Research Development Methods of protecting cells from insults
CA3191819A1 (en) 2020-09-09 2022-03-17 Hazel Szeto Methods and compositions for delivery of biotin to mitochondria
CN117881411A (zh) 2021-06-01 2024-04-12 艾迪雅生物有限责任公司 用于眼部药物的延长释放药物递送系统和使用方法
CN114773433B (zh) * 2022-06-23 2022-09-06 北京肿瘤医院(北京大学肿瘤医院) 一种cd25靶向多肽、分子探针及应用
GB2630566A (en) * 2023-05-22 2024-12-04 Jaguar Land Rover Ltd Apparatus and method for controlling an actuator

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5602100A (en) * 1988-06-30 1997-02-11 Astra Ab Dermorphin analogs having pharmacological activity
EP0350221B1 (en) * 1988-06-30 1996-04-17 Astra Aktiebolag Dermorphin analogs, their methods of preparation, pharmaceutical compositions, and methods of therapeutic treatment using the same
US5118670A (en) * 1988-12-14 1992-06-02 Massachusetts Institute Of Technology Process and composition for increasing brain dopamine release
US5670617A (en) * 1989-12-21 1997-09-23 Biogen Inc Nucleic acid conjugates of tat-derived transport polypeptides
US5858784A (en) 1991-12-17 1999-01-12 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol- and liposome-based delivery
US5674534A (en) 1992-06-11 1997-10-07 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
US5716644A (en) 1992-06-11 1998-02-10 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
IS4261A (is) 1994-02-21 1995-08-22 Astra Aktiebolag Nýir peptíð-ópíóíðar til meðhöndlunar á verkjum og notkun þeirra
ATE255450T1 (de) * 1995-06-09 2003-12-15 Hisamitsu Pharmaceutical Co Matrix für iontophorese
US5849761A (en) * 1995-09-12 1998-12-15 Regents Of The University Of California Peripherally active anti-hyperalgesic opiates
EA001713B1 (ru) 1996-10-07 2001-08-27 Эли Лилли Энд Компани Соединения, полезные для использования в качестве нейрозащитных средств
RU2115660C1 (ru) * 1997-01-28 1998-07-20 Институт биоорганической химии им.М.М.Шемякина и Ю.А.Овчинникова РАН Пептиды, обладающие антистрессорным, противосудорожным и нейропротекторным действием
US5885958A (en) * 1997-03-25 1999-03-23 Administrators Of The Tulane Educational Fund Mu-opiate receptor peptides
US5989463A (en) 1997-09-24 1999-11-23 Alkermes Controlled Therapeutics, Inc. Methods for fabricating polymer-based controlled release devices
CA2314267A1 (en) * 1997-12-10 1999-06-17 Washington University Anti-pathogen system and methods of use thereof
US6417210B1 (en) * 1998-01-09 2002-07-09 Mor-Research Applications Ltd. Treatment of dyskinesias and Parkinson's disease with riluzole and levodopa
JP2002512954A (ja) * 1998-04-24 2002-05-08 マイトコー ミトコンドリア関連疾患を処置するための化合物および方法
US6472378B2 (en) 1998-08-31 2002-10-29 Pro-Neuron, Inc. Compositions and methods for treatment of mitochondrial diseases
US6245740B1 (en) 1998-12-23 2001-06-12 Amgen Inc. Polyol:oil suspensions for the sustained release of proteins
SE9900961D0 (sv) * 1999-03-16 1999-03-16 Astra Ab Novel compounds
AU7855900A (en) * 1999-10-04 2001-05-10 University Of Medicine And Dentistry Of New Jersey Methods for identifying rna binding compounds
US6759520B1 (en) * 1999-10-28 2004-07-06 The New England Medical Center Hospitals, Inc. Chimeric analgesic peptides
US20050192215A1 (en) * 2000-01-21 2005-09-01 Malabika Ghosh Methods and materials relating to novel polypeptides and polynucleotides
EP1303186B1 (en) 2000-07-18 2011-01-26 Cornell Research Foundation, Inc. Medicinal uses of mu-opioid receptor agonists
US6900178B2 (en) * 2000-09-12 2005-05-31 University Of Kentucky Research Foundation Protection against ischemia and reperfusion injury
CA2430409A1 (en) 2000-11-28 2002-06-06 Guilford Pharmaceuticals Inc. Bisubstituted carbocyclic cyclophilin binding compounds and their use
JP2004532187A (ja) 2001-01-25 2004-10-21 ギルフォード ファーマシュウティカルズ インコーポレイテッド 三置換カルボサイクリックサイクロフィリン結合化合物とその用途
US20030077826A1 (en) 2001-02-02 2003-04-24 Lena Edelman Chimeric molecules containing a module able to target specific cells and a module regulating the apoptogenic function of the permeability transition pore complex (PTPC)
SI2656854T1 (sl) * 2003-02-04 2015-09-30 Cornell Research Foundation, Inc. Uporabe aromatsko-kationskega peptida
JP4879020B2 (ja) 2003-05-01 2012-02-15 コーネル リサーチ ファウンデイション インコーポレイテッド 細胞に分子を送達する方法及び担体複合体
US7232824B2 (en) * 2003-09-30 2007-06-19 Scios, Inc. Quinazoline derivatives as medicaments
CA2851972C (en) 2004-01-23 2015-06-23 Cornell Research Foundation, Inc. Methods for reducing oxidative damage
CA2947335A1 (en) * 2005-09-16 2007-03-29 Cornell Research Foundation, Inc. Methods for reducing cd36 expression

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
WU et al..A highly potent peptide analgesic that protects againstischemia-reperfusion-induced myocardial stunning.Am J Physiol Heart Circ Physiol283.2002,283H783-H791. *
张中乐主编.临床病理生理学 1.郑州大学出版社,2002,112-118页.
张中乐主编.临床病理生理学 1.郑州大学出版社,2002,112-118页. *

Also Published As

Publication number Publication date
KR101159254B1 (ko) 2012-06-26
AU2005208821A2 (en) 2005-08-11
CA2554166A1 (en) 2005-08-11
IL256703A (en) 2018-03-29
US20100311664A1 (en) 2010-12-09
CA2851972A1 (en) 2005-08-11
US20160317604A1 (en) 2016-11-03
US8618061B2 (en) 2013-12-31
RU2376028C2 (ru) 2009-12-20
AU2005208821B8 (en) 2010-10-14
JP4931604B2 (ja) 2012-05-16
CA2554166C (en) 2014-07-29
US20070015711A1 (en) 2007-01-18
IL177030A0 (en) 2006-12-10
IL237407B (en) 2018-07-31
US20190328821A1 (en) 2019-10-31
IL235772A (en) 2016-12-29
IL256703B (en) 2020-11-30
KR20070003872A (ko) 2007-01-05
JP2007518818A (ja) 2007-07-12
CA2971928C (en) 2019-01-08
NZ549393A (en) 2009-07-31
US20140349942A1 (en) 2014-11-27
US7781405B2 (en) 2010-08-24
US7550439B2 (en) 2009-06-23
IL177030A (en) 2015-04-30
BRPI0507053A (pt) 2007-06-12
RU2006130431A (ru) 2008-02-27
US9623069B2 (en) 2017-04-18
CA2887797A1 (en) 2005-08-11
CA2971928A1 (en) 2005-08-11
EP1722807A2 (en) 2006-11-22
HK1102289A1 (zh) 2007-11-16
IL237408A0 (en) 2015-04-30
AU2005208821A1 (en) 2005-08-11
CA2971931C (en) 2019-01-08
CA2887797C (en) 2017-09-26
EP1722807A4 (en) 2010-09-15
US9950026B2 (en) 2018-04-24
CA2971929A1 (en) 2005-08-11
CN1938042A (zh) 2007-03-28
US20230149501A1 (en) 2023-05-18
WO2005072295A2 (en) 2005-08-11
CA3024434A1 (en) 2005-08-11
CA2851972C (en) 2015-06-23
US20210015887A1 (en) 2021-01-21
IL237408B (en) 2019-03-31
CA2971931A1 (en) 2005-08-11
AU2005208821B2 (en) 2010-09-30
US20060084606A1 (en) 2006-04-20
ZA200607013B (en) 2008-01-08
CA2971929C (en) 2019-01-08
IL237407A0 (en) 2015-04-30
WO2005072295A3 (en) 2005-09-29

Similar Documents

Publication Publication Date Title
CN1938042B (zh) 芳香族阳离子肽在制备用于减轻氧化性损伤药物中的应用
CN104225574A (zh) 用于防止线粒体通透性改变的方法
HK1102289B (en) Use of an aromatic cationic peptide in preparing the medicaments for reducing oxidative damage
MXPA06008342A (en) Methods for reducing oxidative damage
HK1204999B (en) Methods for preventing mitochondrial permeability transition
HK1131995B (en) Methods for preventing mitochondrial permeability transition
HK1178794B (en) Methods for preventing mitochondrial permeability transition

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1102289

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1102289

Country of ref document: HK

CX01 Expiry of patent term
CX01 Expiry of patent term

Granted publication date: 20100602